BURLINGTON – Global life science giant Labcorp is rolling out a test that it says can speed up a diagnosis for Alzheimer’s and thus lead to earlier intervention to fight the deadly disease. The test ...

BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

(Reuters) - Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

The clinical services giant Labcorp is rolling out its first blood test to help identify and confirm the signs of multiple neurodegenerative diseases and brain injury, including ALS, dementia and ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...

Innovative GFAP blood biomarker test expands Labcorp's (LH) portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...